FEATURED EDITORIAL
Two downstream biologics processing experts address some of the field's complex, nagging questions about mitigating host cell proteins.
- EMA Guideline On Clinical-Stage ATMPs Comes Into Effect: On The Verge Of Convergence?
- Formulation Development Of A JAK1 Inhibitor Extended-Release Tablet
- Late-Stage Formulation Is A Different Ballgame. Insights From An Allstar
- Exploring The Market For Closed-Loop Cell Therapy Production
- Closed-Loop Manufacturing Is The Cell Therapy Revolution We Need
- How A Biotech Navigates the CDMO Frenzy For GLP-1 Services
- What Global Survey Says About Scant Patient Access To CAR-T Therapy
GUEST COLUMNISTS
-
EMA Guideline On Clinical-Stage ATMPs Comes Into Effect: On The Verge Of Convergence?
On July 1, 2025, the EMA’s Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials is slated to come into effect.
-
Formulation Development Of A JAK1 Inhibitor Extended-Release Tablet
This scientific article presents a summary of the formulation development strategy of a JAK1 inhibitor extended-release tablet, with a focus on experimental design, data interpretation, and formulation decision-making.
-
Exploring The Market For Closed-Loop Cell Therapy Production
The second part of a discussion on closed-loop systems explores the CDMO and equipment landscape for scaling automated closed loop cell therapy manufacturing systems.
-
Closed-Loop Manufacturing Is The Cell Therapy Revolution We Need
In cell therapy manufacturing, automated closed systems with integrated software controls offer numerous benefits over traditional open systems.
-
What Global Survey Says About Scant Patient Access To CAR-T Therapy
The Worldwide Network for Blood and Marrow Transplantation initiated a survey to understand cost, infrastructure, and regulatory differences affecting access.
-
Scaling Up Manufacturing? Here's Why You Need A CMC Specialist
CMC experts (whether in-house or outsourced) fill a vital role during the transition from small-scale production to larger operations for maintaining quality, consistency, and compliance.
-
Amgen Bets On Agility In The Age Of AI
The company is speeding up process optimization with tools like predictive analytics, digital twins, and generative AI copilots.
-
Peeling Back The Layers Of Radiolabeled Peptide Production
From the moment radiolabeled drugs are made, it’s a race to get them to patients. Radioactive decay is just one of many complications. Here’s one company’s approach.
PHARMA OUTSOURCING WHITE PAPERS
-
Overcoming Challenges To High-Concentration Formulation Development
Explore how the S-HiCon™ platform optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.
-
Outsourcing Stability Storage: A Cost-Effective And Quality-Driven Approach
Partnering with a leader in outsourced stability storage is revolutionizing the pharmaceutical and medical device industry by saving costs and resources, and ensuring product quality and compliance.
-
A New Framework For Identifying Nitrosamine Risks And Derisking Products
Examine a new methodology that holds significant promise for identifying APIs at risk for NDSRI formation, enabling manufacturers to prioritize risk mitigation strategies and ensure compliance.
-
Vial Fogging: Practical Considerations For Vial Selection
Vial fogging is a common phenomenon observed in lyophilized biologic drug products. This document presents two case studies that explore critical factors contributing to vial fogging and inform vial selection decisions.
-
Mitigating Nitrosamine Risks In Pharmaceuticals
Nitrosamines can come from a range of sources, including raw materials, manufacturing processes, and even water sources. Detecting them requires sensitive analytical methods.
-
The Relevance Of Polymorph Screening In The Pharmaceutical Industry
Polymorph screening identifies different solid forms of active pharmaceutical ingredients, optimizing drug stability, solubility, and manufacturability. This process ensures quality, regulatory compliance, and intellectual property protection in pharmaceutical development.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- CDMO Uses Robotic Gloveless Isolator For Advanced Therapeutics
- Analytical Method Release And Stability Platform For RNA Drug Substance
- Scalability And Performance Of Mobius® iFlex Bioreactors
- Getting CMC Right For Emerging Technologies
- Leveraging High-Pressure Sterile Filtration For Highly Viscous Solutions
NEWSLETTER ARCHIVE

REPORTING: TRUMP VS. PHARMA?
- Tariffs On Toys … And API? Biopharma As The Next Battleground
- Evolve Or Fade Away? Biotech's Outsourcing Moment In Trump's Tariff Tangle
- Lilly's CEO Building On The Trump Agenda
- Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs
- CDMOs Bet Big On Asia Expansion. Can Trump Reverse The Tide?
- What If The Trump Tariff Strategy Works?
REPORTING: U.S. BIOSECURE ACT
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Streamlining Drug Development: From Developability Assessment To High-Concentration Formulation Development
- Unlocking Efficiency In Large-Scale Microbial Manufacturing
- The Role Of Developability In Lead Candidate Selection
- Flexibility To Meet Your Process Needs
- Prevent Batch Failures Before They Happen